Principles of Hepatic Artery Infusion Therapy
Hepatic Artery Infusion (HAI) therapy leverages the unique anatomy of the liver and properties of floxuridine to deliver high doses of regional therapy safely and effectively to tumors in the liver, limiting toxicity elsewhere in body.
While normal parenchyma is perfused primarily by the portal vein, liver metastases derive their blood supply from the hepatic artery.
HAI therapy delivers chemotherapy directly into the liver via the hepatic artery, resulting in concentrations of the drug in liver metastases that are ~400 times higher than those achieved by IV administration 1.
First pass liver metabolism of ~97% and a half-life of ~10 minutes, results in minimal systemic exposure and toxicity of floxuridine.
Patient Selection Considerations for HAI Therapy2
- Histologically confirmed CRC or iCCA with radiographic or pathologic evidence of tumors in the liver
- Fit to undergo a major abdominal operation (Eastern cooperative Oncology Group (ECOG) 0-1)
- No clinical, laboratory or radiographic evidence of portal hypertension or portal vein thrombosis
- Preserved hepatic function, total bilirubin <1.5 mg/dL
- Favorable hepatic anatomy (patent GDA with adequate length and caliber)
- Any patient that has been resected and has preserved hepatic function